A monoclonal antibody -- a protein created in a lab which mimics the work of a natural antibody -- could be highly effective ...

Nirsevimab, a monoclonal antibody, is highly effective in real-world conditions at preventing severe respiratory syncytial ...

A clinical trial is underway to assess the effectiveness and safety of sipavibart, AstraZeneca's long-acting monoclonal antibody designed to provide protection against Covid-19, as a potential ...

The US Food and Drug Administration has approved nipocalimab-aahu, a new FcRn- blocking monoclonal antibody, for the ...

Johnson & Johnson's (J&J) human neonatal Fc receptor (FcRn)-blocking monoclonal antibody Imaavy (nipocalimab-aahu) has ...

The FDA has approved a monoclonal antibody to treat individuals aged 12 years and older with generalized myasthenia gravis ...

Nipocalimab (Imaavy; Johnson & Johnson), an FcRn-blocking monoclonal antibody, was approved for patients 12 years and older ...

The US Food and Drug Administration (FDA) recently announced a strategic roadmap to phase out animal testing requirements for ...

A medication used in dogs suffering from osteoarthritis is facing backlash after thousands of patients have experienced ...

Johnson & Johnson ’s anti-FcRn antibody nipocalimab has been approved by the FDA to treat generalized myasthenia gravis. The drug will be marketed under the brand name Imaavy.

Researchers in Korea generated a new method for generating CHO cell lines with significantly higher productivity, efficiency, ...